SOL SHERRY, M.D.
The present decade will probably show the extent to which thrombolytic therapy can be applied for benefit in the management of thromboembolic occlusive vascular disease. Two agents, streptokinase and urokinase, when used in appropriate dosage, have been shown to produce in vivo an active thrombolytic state. Although the experience with each differs markedly (a hundredfold greater with streptokinase), both agents are being evaluated under practical clinical circumstances that should define their usefulness as well as their indications, contraindications, and hazards.
The recent publication of several symposia on thrombolytic therapy with streptokinase (1, 2)
SHERRY S. Streptokinase Therapy for Thromboembolic Occlusive Vascular Disease. Ann Intern Med. ;74:437–440. doi: 10.7326/0003-4819-74-3-437
Download citation file:
Published: Ann Intern Med. 1971;74(3):437-440.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use